AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

Appointees include world-renowned bioinformatics expert Prof. Charlotte Deane and veterans in drug development and the FDA approval process, including Dr. Eric Rowinsky

AI Proteins, a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, announced the formation of a Scientific Advisory Board. The board will provide deep industry expertise and insights to fast-track the company’s efforts to bring next-generation therapeutics to market.

AiThority Interview Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab

“I am excited by the unique way AI Proteins uses precision computational techniques combined with artificial intelligence to design miniproteins for specific disease profiles and challenges”

The eight-member board consists of: Alice Bexon, MD; Charlotte Deane, PhD; Todd Fehniger, MD, PhD; Justin Gainor, MD; Dennis Klinman, MD, PhD; Carl Novina, MD, PhD; Eric Rowinsky, MD; and Omer Yilmaz, MD, PhD.

“I am delighted to welcome this incredible group of physicians and scientists,” said Chris Bahl, founder, President, and CSO of AI Proteins. “We are excited about the depth and breadth of experience this distinguished group brings to AI Proteins, and we believe their guidance will be invaluable in advancing our mission to engineer novel miniprotein-based medicines to help patients as fast as we can.”

AI Proteins has built a high-throughput drug discovery platform that gives the company the unique ability to engineer and optimize therapeutic proteins at unprecedented speed to target a wide range of diseases. The Scientific Advisory Board will provide important guidance in helping to select therapeutic candidates to advance into further development.

Among the luminaries on the newly-formed board, Prof. Charlotte Deane MBE has the distinction of being one of the world’s top experts on structural bioinformatics. In her current position as Chief Scientific Officer – AI at Exscientia, she focuses on AI, machine learning, and protein design and discovery. AI Proteins values the opportunity to collaborate with Prof. Deane, who is doing exceptional work in the field and will bring an additional perspective to the company.

Read More about AiThority Interview: AiThority Interview with Elliott Jobe, Chief Innovation Officer and Co-Founder at Infinite Reality

“I am excited by the unique way AI Proteins uses precision computational techniques combined with artificial intelligence to design miniproteins for specific disease profiles and challenges,” said Prof. Deane. “By using de novo design, AI Proteins can wield a tremendous amount of control over the function and properties of each protein to create therapeutics that are more effective in solving unmet medical needs.”

The FDA drug approval process will play an important role as the company moves candidates into further development, which is why AI Proteins looked for scientific advisory board members who are well-versed in clinical development, securing FDA approvals, and who deeply understand the many complexities involved.

Dr. Eric Rowinsky has spent many years developing therapeutics for cancer and preparing molecules for FDA approval. He has had executive-level roles at Hummingbird Bioscience, Inspirna (formerly Rgenix), Stemline Therapeutics, and Imclone Systems. Dr. Rowinsky has also served as an Adjunct Professor of Medicine at New York University School of Medicine. “Securing FDA approval for new drugs is notoriously complex—and rightly so,” said Dr. Rowinsky. “The FDA wants to ensure the efficacy and safety of any drug released on the market, and I look forward to helping AI Proteins demonstrate the tremendous advantages of its miniprotein therapeutics as it looks to move its first products into the clinic.”

 Latest AiThority Interview Insights : AiThority Interview with Dorian Selz, Co-Founder & CEO at Squirro

 [To share your insights with us, please write to sghosh@martechseries.com]